CRISPR Therapeutics AG (CRSP) closed the latest trading day at $41.22, indicating a +0.12% change from the previous session's end. This change outpaced the S&P 500's 0.08% gain on the day. On the ...

A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

Bioengineering professor and The Grainger College of Engineering's Dean, Rashid Bashir, led a team of researchers in a ...

The latest trading session saw CRISPR Therapeutics AG (CRSP) ending at $41.17, denoting a -1.84% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0 ...

The competition between U.S. and Chinese biotech companies is particularly fierce in one field: CRISPR gene editing. Here are ...

Gene therapy pioneer Jim Wilson and researcher Kiran Musunuru are using contrasting approaches to overcome “irrational ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

The blueprints for these molecules can be found in the ... CRISPR-Cas Technology: Balancing Efficiency and Safety Dec. 4, 2024 — Researchers have uncovered a serious side effect of using the ...

University of Illinois at Urbana-Champaign researchers have developed a CRISPR-based diagnostic tool capable of detecting ...

Elsewhere, the Dow saw a downswing of 0.03%, while the tech-heavy Nasdaq ... Right now, CRISPR Therapeutics AG possesses a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...